Corebridge Financial Inc. Has $2.67 Million Holdings in CG Oncology, Inc. (NASDAQ:CGON)

Corebridge Financial Inc. cut its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 31.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,189 shares of the company's stock after selling 42,440 shares during the period. Corebridge Financial Inc. owned approximately 0.12% of CG Oncology worth $2,673,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. State Street Corp lifted its position in shares of CG Oncology by 73.0% in the third quarter. State Street Corp now owns 1,700,653 shares of the company's stock worth $64,166,000 after buying an additional 717,722 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of CG Oncology by 876.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 26,660 shares of the company's stock valued at $1,006,000 after acquiring an additional 23,931 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in CG Oncology by 114.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 379,664 shares of the company's stock worth $14,325,000 after purchasing an additional 202,262 shares during the last quarter. JPMorgan Chase & Co. boosted its position in CG Oncology by 59.1% during the third quarter. JPMorgan Chase & Co. now owns 31,071 shares of the company's stock worth $1,172,000 after purchasing an additional 11,542 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new position in CG Oncology during the fourth quarter valued at approximately $411,000. 26.56% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Monday, March 31st. TD Cowen began coverage on shares of CG Oncology in a research report on Tuesday, January 7th. They set a "buy" rating for the company. Morgan Stanley restated an "overweight" rating and set a $55.00 price target on shares of CG Oncology in a report on Friday, March 7th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $66.00 price objective on shares of CG Oncology in a research note on Friday, December 6th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $63.88.

Insider Buying and Selling

In other news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

CG Oncology Price Performance

Shares of NASDAQ CGON traded down $1.54 during mid-day trading on Friday, hitting $17.20. The company had a trading volume of 2,148,002 shares, compared to its average volume of 679,538. CG Oncology, Inc. has a 12 month low of $16.64 and a 12 month high of $46.99. The firm has a market cap of $1.31 billion, a P/E ratio of -12.11 and a beta of 1.24. The business's 50-day simple moving average is $26.99 and its 200-day simple moving average is $31.30.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). The firm had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.11 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. As a group, sell-side analysts predict that CG Oncology, Inc. will post -1.31 EPS for the current year.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.